<DOC>
	<DOCNO>NCT00021216</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Phase I trial study effectiveness bortezomib treat child advance solid tumor respond previous treatment .</brief_summary>
	<brief_title>Bortezomib Treating Children With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose bortezomib pediatric patient refractory solid tumor . II . Determine dose-limiting toxicity toxic effect regimen patient . III . Preliminarily determine antitumor activity regimen patient . OUTLINE : This dose-escalation study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . If dose-limiting toxicity form myelosuppression occur stratum I , dose escalation continue patient meet qualification stratum II . PROJECTED ACCRUAL : Approximately 24-36 patient accrue study .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm solid tumor refractory standard therapy standard therapy exist Histologic confirmation require brainstem glioma optic pathway tumor Ineligible therapies high priority Stratum II : No bone marrow involvement Performance status Karnofsky 50100 % ( 10 year age ) Performance status Lansky 50100 % ( 10 year age ) At least 8 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 75,000/mm^3 ( transfusion independent ) Hemoglobin least 8 g/dL ( RBC transfusion allow ) Bilirubin le 1.5 mg/dL ALT le 5 time normal age Albumin least 2 g/dL Creatinine great upper limit normal age Creatinine clearance radioisotope glomerular filtration rate great 70 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficit relate CNS tumor allow relatively stable least 2 week No uncontrolled infection At least 7 day since prior biologic therapy recover At least 3 month since prior allogeneic stem cell transplantation At least 1 week since prior growth factor Stratum II : No prior stem cell transplantation without total body irradiation At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) recover Stratum II : No 2 prior multiagent chemotherapy regimens More 2 singleagent regimen allow Concurrent dexamethasone allow CNS tumor stable dose least 2 week See Biologic therapy At least 2 week since prior palliative local radiotherapy At least 6 month since prior craniospinal radiotherapy radiotherapy least 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy Recovered prior radiotherapy Stratum II : No prior radiotherapy 20 % bone marrow No prior bortezomib No concurrent anticonvulsants No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>